• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    PCI Pharma Services

    Syngene

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Flow Sciences

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Improving Your Development Program

    Seven lab science trends driving the future of drug development.

    Improving Your Development Program
    Related CONTENT
    • CENTOGENE Appoints AI Director
    • Three Key Challenges for Wide-Scale AI Adoption in Pharma
    • Leveraging Deep Learning in Drug Research
    • Celgene Enters AI Drug Discovery Deal with Exscientia
    • 2019 Trends & Predictions
    Jenifer Vija, Liam Moran, Chris Loosbroock and Eric Snyder, Charles River05.07.19
    The quality of laboratory science services can make or break drug development, keeping you on track or derailing your program altogether. A well-planned approach may even accelerate your timelines and make the difference in being first to market. Yet, many drug developers are at a loss when it comes to this critical aspect of their program, unsure how best to proceed. Many factors fuel this uncertainty, as we witness the arrival of new technologies, the rise of new types of therapies and modalities, and the downsizing of biotech and pharma’s internal drug development teams. To be certain, there are challenges to overcome. Will the latest trends in laboratory support services offer us solutions?

    Cell, gene, and other biologic therapies
    Therapies based on biological matter represent a whole new wave of drug development. Though filled with promise, these types of therapies also introduce a unique set of analytical challenges. By contrast, analytical and regulatory expectations for traditional small molecule bioanalysis are clear. As we move into therapies that are mixed, cell-based, or even oncolytic viruses, for example, their vanguard nature makes it difficult to “get it right.” Reliable data is needed to make better decisions, but we are often left wondering, how do we analyze this? Do we have the right equipment to obtain results? How do we get the information we need?

    These therapies often require complex method development and validation and new technologies and methods for data analysis. In addition, dose formulation for biologics, nanoparticles, and mixed-construct molecules also require a larger suite of technical capabilities, with different types of detectors and even different types of staff from those found in laboratories that support small molecule analysis. These substantial requirements need not deter you from pursuing the development of a cell-based therapy, but those venturing into this space should anticipate the differences from small molecule development and create a thoughtful plan to address these needs.

    Increasing collaboration and consultation
    More and more, today’s drug developers are actively seeking guidance and advice to move their program along. The combination of new therapy types (e.g., cell and gene) and constantly evolving regulatory guidelines has made knowing what to analyze and how to proceed unclear. The proliferation of new guidance documents from around the world—the ICH, Japan, Europe, and other authorities—creates rules that are more complicated, but not always prescriptive for today’s newer therapies that, in their complexity, defy our ability to articulate best practices. How do we assess its safety? How do we determine relevant endpoints? When a regulatory path for a molecule is not defined, developers must rely on the intellectual capital and experience of those who have gone before and can offer guidance based on what they’ve seen.

    Seasoned advisors can determine which guidances are most applicable to the goals of the program, evaluate what has been done in the past, and apply these methods to like scenarios. The resulting collaboration stands to benefit drug developers of all kinds as we share data and create precedents that help smooth the path to clinic.

    Outsourcing
    With the overall downsizing of biotech and pharma operations and the rise of virtual companies, many drug developers lack the regulatory experience, laboratory facilities (dedicated space and technology), or subject matter experts who can properly design and run a program end-to-end. Especially with therapies like nanoparticles, cell, and gene therapies, you need to develop a strategy that focuses on obtaining answers to key questions to optimize your time and efforts.

    Moreover, there are numerous elements—regulatory specifications, materials, and methods—that need to be in place before you are ready to go, and many developers don’t rely on outside expertise to focus on the scheduling accuracy of the inputs required before a study begins, including reference standards, test article formulation, procurement of study animals, etc. Sometimes, it is not clear what technology will best serve new and emerging therapeutics; organizations need to have a wide selection of technologies on hand to deal with the diversity of therapies in development.

    From a logistics standpoint, a program can require a lot of different assays being conducted in many different locations, adding to both the scientific and managerial complexity of the project. Thus, more and more developers are choosing to outsource their analytical work with entities like contract research organizations who not only have the breadth of equipment and scientific skill to handle any type of drug in development, but the expertise to advise the best approach. Those who outsource at the earliest stages stand to benefit the most, as assistance with planning a program can result in real advantages in overall program development timelines.

    Biomarkers
    Whether you are evaluating pharmacodynamic parameters or assessing safety, it is important to create studies that include relevant endpoints. Biomarkers illuminate how a drug will influence the target and adjacent systems. We need research-based answers, so we know what to expect later (e.g., when we get to first-in-human doses).

    Biomarkers are a hot topic, with abundant sources for lists of available biomarkers, applicable species, and associated ranges. However, with the newest classes of therapies, there is little data to support their development. How will the drug function in naïve animals? What is an adequate response? What are the relevant ranges? Novel therapeutics don’t often have a readily available relevant assay, and there is no end-all, be-all approach to identifying the right endpoints. The process starts in method development, with incurred samples from another trial to figure out the necessary ranges. Method development, then, is an iterative process to get to where you need to be. This is another scenario in which outsourcing to an experienced provider can help you taper the number of endpoints you ultimately examine and save you time and money.

    Microsampling
    How many samples need to be collected on the study to provide the most information for the program? Typical programs require sample collections to monitor exposure, clinical chemistry, pharmacodynamic markers and biomarkers. When biomarkers have been established, how will samples be collected? Providing many benefits to models and developers alike, microsampling is a trend that won’t be going away any time soon. But, those who wish to support the 3Rs by using this technique are often unaware of the analytical work that is required up front to ensure that the method is feasible for their therapy. Will microsampling sacrifice sensitivity for study design?

    Over the last decade, equivalent data to standard collection procedures has been presented for microsampling and reduced volume techniques. You need to first verify that the exposures you can measure with a limited sample volume are going to serve your program. Running studies that prove your data will be acceptable to regulatory authorities will help de-risk your program. These preliminary studies can be costly, but the investment can be offset by the ability to collect more data from one study—with more samples that serve multiple endpoints—and by the reduction in the number of research models you ultimately require. If you decide to cut over mid-study, regulatory agencies may require bridging bioequivalent studies between the two techniques to verify that there is no disconnect between them. Choosing to microsample is a delicate balance between regulatory acceptance and doing the right thing from a 3Rs perspective, but still worthy of consideration.

    Technology and automation
    There is no shortage of new technology to support the business of drug development. New equipment arrives on the scene and more is in development every day. Some experts predict there will soon be instruments and techniques, for example, that are capable of multiplexing different types of analyses (e.g., PK, biomarkers, and immunogenicity). While a boon to the field of laboratory science, organizations must continuously evolve, making robust, regular investments in technology like LIMS, Provantis, ELN, and other systems that ease management and support faster turnaround. Of course, challenges exist with adopting new technology.

    Often, the proliferation of new technologies results in an abundance of data, which must then be stored, managed, and analyzed. Every new system requires training at multiple levels of personnel, and the existence of multiple systems can make it difficult for data to be shared between them. The gains, however, far outweigh the difficulties, and the expectation is that laboratory science facilities will have access to the latest and greatest technology. Some labs prepare by getting in on the ground floor, engaging in working partnerships with the companies that design and manufacture these technologies in the interest of developing new features that meet their desired specifications. This results in overall wins for the industry.

    As for data, cloud services would appear to be the optimum solution for the electronic lab book, where unlimited data can be securely stored and accessible from anywhere around the globe. Such a configuration fosters data sharing and collaboration between multiple sites, which can be key to reducing timelines. Smaller labs are blazing the path in this area, while drug developers and contract labs alike work to accept and trust the certification of a system that they can’t see. In many organizations, the paper trail remains the only source of confirmation for QA/QC and regulatory auditors who may not be trained on the different systems that produce data, so this aspect of the technology trend may take more time to be fully adopted.

    The use of artificial intelligence (AI) in the laboratory science space is still limited, despite the need to analyze the tremendous amount of data that comes from even a single study. As with the training required for new systems, AI likewise needs a substantial investment of time from human counterparts to accurately “learn” and thus automate roles once performed by people. That is not to say it’s not on the horizon. Even now, there are tools that exist that allow one system to maintain and analyze vast amounts of data—for example, flow cytometry results—effectively simplifying and streamlining the process and requiring less manpower.

    Accelerating timelines
    Perhaps the biggest trend of all is the desire to speed up the development process. The future is wide open for the arrival of unique therapies, but time is still of the essence. In today’s competitive market, if you’re not first, you’re last. Everyone wants to shave days, months, or even years off their development cycles. How do you do that? Isn’t that the million-dollar question.

    It’s important to remember a trend is just a trend, and not everyone who jumps on the bandwagon will succeed. Drug development is filled with challenges, and your decisions around bioanalysis play a key role in your ability to meet milestones. Regardless of the tools and resources you choose to use, anticipation and careful planning of next steps is critical—from the outset of your program all the way through to the end.
    Related Searches
    • study
    • Outsourcing
    • quality
    • artificial intelligence
    Suggested For You
    CENTOGENE Appoints AI Director CENTOGENE Appoints AI Director
    Three Key Challenges for Wide-Scale AI Adoption in Pharma Three Key Challenges for Wide-Scale AI Adoption in Pharma
    Leveraging Deep Learning in Drug Research Leveraging Deep Learning in Drug Research
    Celgene Enters AI Drug Discovery Deal with Exscientia Celgene Enters AI Drug Discovery Deal with Exscientia
    2019 Trends & Predictions 2019 Trends & Predictions
    Implementing AI in Drug Discovery Implementing AI in Drug Discovery
    Personalized Medicine: Getting More Out of Clinical Trials Personalized Medicine: Getting More Out of Clinical Trials
    Emerald Health, Lonza Enter Large-Scale Mfg. Pact Emerald Health, Lonza Enter Large-Scale Mfg. Pact
    Avadel Pharma Restructures Avadel Pharma Restructures
    Leveraging AI to Advance Discovery, Development and Delivery Leveraging AI to Advance Discovery, Development and Delivery
    Fortress Enters Devt. Deal with Alexion Fortress Enters Devt. Deal with Alexion
    Fortress Fortress' Caelum Enters Partnership with Alexion
    AI in Pharma: Transforming Data into Drugs AI in Pharma: Transforming Data into Drugs
    Rising Demand for Lyophilized Products Rising Demand for Lyophilized Products
    Bavarian Nordic’s Smallpox Vax Gets Priority Bavarian Nordic’s Smallpox Vax Gets Priority

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • Drug Development | Preclinical Outsourcing
      Preclinical Planning for Successful Drug Development

      Preclinical Planning for Successful Drug Development

      When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.
      Mingyi Trimble, WuXi AppTec 09.09.20


    • APIs | Drug Development | Risk Management
      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.
      Sarah Bethune, Cambrex 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Drug Development | Regulatory Affairs
      Guidelines in Toxicology: A Blessing and a Curse

      Guidelines in Toxicology: A Blessing and a Curse

      A look at the evolution of drug development regulatory guides.
      Sarah Gould, Senior Principal Scientific Advisor, Charles River 09.16.19


    • Drug Development
      Flex Your Outsourcing Model to Maximize Drug Development

      Flex Your Outsourcing Model to Maximize Drug Development

      How to choose—and optimize—combinations of service models to fit your needs.
      Timothy King, Executive Director, Functional Service Partnerships (FSP), PPD 09.16.19

    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Drug Development
      Technical Advantages of Continuous Flow Chemical Synthesis

      Technical Advantages of Continuous Flow Chemical Synthesis

      Continuous flow chemistry is known for its ability to handle hazardous reactions safely, but can also unlock many other technological benefits.
      Shawn Conway, Engineering R&D Director, Cambrex High Point 04.05.19


    • Drug Development | Preclinical Outsourcing
      Early Development Trends

      Early Development Trends

      Catalent’s president of oral drug delivery, Jonathan Arnold, talks trends and challenges in the early phases of drug development.
      Tim Wright, Editor, Contract Pharma 03.06.19

    • Drug Development
      Future Trends in the CDMO Space

      Future Trends in the CDMO Space

      And how to navigate them for successful drug development
      Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma 01.25.19

    • APIs | Cytotoxics and High Potency Manufacturing | Drug Development
      CDMOs On The Rise

      CDMOs On The Rise

      Tracking growth and strategies in the CDMO business
      Michel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19


    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    • Drug Development
      Streamlining Drug Development:

      Streamlining Drug Development:

      Four key takeaways from Veeva’s 2018 R&D Summit
      Henry Levy, General Manager of Vault CDMS, Veeva Systems 11.13.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    Ipsy Adds New Personal Care Brand
    John Masters Organics Rolls Out Roll-On Fragrances
    Weleda Celebrates 100 Years of Beauty
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login